Drug Profile
Balcinrenone - AstraZeneca
Alternative Names: AZD-9977Latest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Acetamides; Benzoxazines; Cardiovascular therapies; Fluorinated hydrocarbons; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Heart failure; Kidney disorders
- Discontinued Cardiovascular disorders; Diabetic nephropathies
Most Recent Events
- 19 Mar 2024 AstraZeneca plans a phase III trial in Chronic heart failure (Combination therapy) in USA, Argentina, Australia, Austria, Canada, Chile, China, Colombia, Czech Republic, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, South Kores, Malaysia, Mexico, Netherlands, Peru, Philippines, Poland, Romania, Slovakia, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, Vietnam (NCT06307652)
- 22 Sep 2023 AstraZeneca completes the phase II MIRACLE trial in Chronic heart failure (Combination therapy, In adults, In the elderly) in Hungary, Belgium, Bulgaria, Canada, Czech Republic, Denmark, Germany, Italy, Japan, Lithuania, Poland, Russia, Slovakia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine (NCT04595370)
- 08 May 2023 Nuremberg Clinic initiates a phase II DapaBalci-Leap trial for Kidney disorders (Combination therapy, In the elderly, In adults) in Germany and France (PO) (NCT05884866)